Jeannie Hou, MD

Vice President, Clinical Development
Replimune Inc., United States

Presentation(s):

• 60: Safety, efficacy, and biomarker assessment of RP1 in combination with nivolumab in patients with advanced skin cancers

  Friday, March 24, 2023
  10:54 AM – 11:04 AM

  Disclosure information not submitted.